Borrelia burgdorferi Co-Localizing with Amyloid Markers in Alzheimer's Disease Brain Tissues.
Level 4 - case-series / case-control
Post-mortem case-control tissue analysis combined with in vitro laboratory experiments
PubMed 34897095 · doi:10.3233/JAD-215398
What was done
Researchers examined post-mortem brain tissue sections from patients diagnosed with Alzheimer's disease (AD) or Parkinson's disease, alongside age-matched controls, to detect Borrelia burgdorferi antigen and DNA. Immunohistochemical staining was used to assess whether positive Borrelia structures co-localized with the biofilm marker alginate and AD markers (amyloid-β and phospho-tau [p-Tau]). Additionally, two mammalian cell lines were infected with B. burgdorferi in vitro to evaluate subsequent changes in amyloid-β and p-Tau expression.
What was found
The abstract reports no numerical values, sample sizes, or statistical metrics. It qualitatively reports the presence of B. burgdorferi antigen and DNA in brain tissues of patients with AD pathology, noting that one patient had a clinical history of Lyme disease. Borrelia-positive structures co-localized with alginate as well as amyloid-β and p-Tau markers. In vitro infection of two mammalian cell lines with B. burgdorferi resulted in reported increases in amyloid-β and p-Tau expression.
Why it matters
This study provides descriptive evidence linking B. burgdorferi presence and biofilm formation to classic AD neuropathological hallmarks in autopsy tissue, supporting hypotheses regarding infectious etiologies or contributors to neurodegeneration.
Limits
The abstract lacks all quantitative data, including the total sample size (n), specific proportions of positive cases versus controls, and effect sizes. As an observational post-mortem and in vitro study, it cannot establish whether B. burgdorferi infection causes AD pathology or merely colonizes pre-existing neuropathology.
Cited by
- supports Autopsy studies of Alzheimer's patients reveal biofilms, amyloid, and phosphorylated tau in the brain.